KATO III Xenograft Model Service for Gastric Cancer

The KATO III Xenograft Model Service for Gastric Cancer provides a robust, clinically relevant platform for evaluating novel therapeutic agents against poorly differentiated gastric adenocarcinoma with FGFR2 amplification. Alfa Cytology, as a dedicated preclinical CRO, delivers end-to-end KATO III xenograft model services---from cell line authentication and tumor inoculation to comprehensive pharmacodynamic and pharmacokinetic endpoint analysis---enabling researchers to accelerate their oncology drug development pipeline with confidence and reproducibility.

Overview of KATO III Xenograft Model for Gastric Cancer

The KATO III cell line, originally established from a pleural effusion of a 55-year-old Asian male with metastatic gastric carcinoma, represents a poorly differentiated adenocarcinoma subtype characterized by FGFR2 gene amplification and constitutively active FGFR2 kinase signaling. In xenograft settings, KATO III tumors demonstrate robust subcutaneous engraftment in immunodeficient mice (e.g., BALB/c nude mice, NOD/SCID mice) with dose-dependent tumor growth kinetics, and have been extensively validated as a predictive model for FGFR2-targeted therapies including AZD2171, AZD4547, and dovitinib. The cell line exhibits intermediate sensitivity to conventional chemotherapeutic agents such as 5-fluorouracil and cisplatin, with documented chemoresistance mechanisms linked to APEX1-Jagged-1 signaling activation, making it particularly valuable for studying drug resistance and combination therapy strategies in gastric cancer preclinical research.

Beyond subcutaneous applications, KATO III has demonstrated utility in peritoneal metastasis models when administered via intraperitoneal injection at high cell densities (>=100x10^6 cells), enabling the study of malignant ascites formation and peritoneal carcinomatosis---two major causes of gastric cancer mortality. The model's FGFR2-amplified molecular profile, combined with its well-characterized growth parameters and established responsiveness to both targeted and cytotoxic agents, positions the KATO III xenograft as a versatile and translationally relevant tool for evaluating novel therapeutic modalities, biomarker-driven drug selection, and resistance mechanism investigations in gastric cancer drug development.

Figure 1. Animal survival benefits of nintedanib and cytotoxic agents. (Kalnina Z, et al., 2025)

Cell Line Information: KATO III

KATO III is a human gastric cancer cell line with well-documented origins, molecular characteristics, and experimental properties. The table below summarizes key information essential for researchers utilizing this cell line in xenograft model development.

Our Services

Alfa Cytology leverages the KATO III cell line's unique molecular profile and established tumorigenic properties to deliver comprehensive, reproducible xenograft model services tailored to your preclinical research objectives. Our integrated service platform encompasses cell line authentication via STR profiling, optimized tumor inoculation protocols across multiple implantation sites (subcutaneous, intraperitoneal, and orthotopic), real-time tumor monitoring through caliper measurement and bioluminescence imaging, and rigorous endpoint analysis including tumor growth inhibition, body weight monitoring, histopathological evaluation, and pharmacokinetic sampling. With extensive experience in FGFR2-targeted therapy studies and chemoresistance model development, Alfa Cytology ensures that every KATO III xenograft study is executed with scientific precision, regulatory compliance, and operational transparency to accelerate your oncology drug candidate from bench to clinical readiness.

Workflow of KATO III Xenograft Model Construction

The construction of a KATO III xenograft model follows a standardized, multi-phase workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility. Each phase integrates quality control checkpoints to validate cell viability, sterility, and genetic identity before proceeding to in vivo stages.

1. Step 1: Cell Line Authentication and Expansion: KATO III cells are retrieved from authenticated stocks (ATCC) and expanded under standard culture conditions (RPMI-1640 + 10% FBS, 37 degrees C, 5% CO2). Prior to inoculation, cells undergo STR profiling verification to confirm genetic identity, mycoplasma testing to ensure sterility, and viability assessment (typically >95% viability by trypan blue exclusion) to guarantee robust engraftment potential.
2. Step 2: Immunodeficient Mouse Preparation: Age-matched immunodeficient mice (commonly 4-6-week-old female BALB/c nude mice or NOD/SCID mice) are acclimatized for 7-14 days under specific pathogen-free (SPF) conditions. Baseline body weights are recorded, and mice are randomized into treatment groups based on weight stratification to minimize inter-group variability.
3. Step 3: Tumor Cell Inoculation: KATO III cells are harvested at logarithmic growth phase, washed with PBS, and resuspended at the appropriate concentration. For subcutaneous models, 1x10^6 cells in 100 microL PBS (often mixed with Matrigel for enhanced engraftment) are injected into the bilateral flank regions. For peritoneal metastasis models, 100x10^6 cells in 1 mL PBS are administered via intraperitoneal injection. For orthotopic or hepatic models, specialized surgical techniques (e.g., portal vein injection in NOD/SCID mice) are employed.
4. Step 4: Tumor Monitoring and Randomization: Tumor growth is monitored by external caliper measurement (subcutaneous models) or non-invasive imaging (bioluminescence/fluorescence imaging for metastatic models) every 2-3 days. Once tumors reach the target volume (typically 100-150 mm^3 or ~5 mm diameter), mice are randomized into vehicle control and treatment groups to ensure comparable baseline tumor burdens across cohorts.
5. Step 5: Treatment Administration and In-Life Monitoring: Test compounds are administered via the designated route (oral gavage, intraperitoneal, intravenous, or subcutaneous) according to the study protocol. Body weights, clinical signs, and tumor dimensions are recorded at defined intervals. Tumor volume is calculated using the modified ellipsoid formula: V = (length x width^2) / 2. Dosing adjustments are made based on body weight changes to maintain therapeutic exposure.
6. Step 6: Endpoint Analysis and Sample Collection: At study termination, mice are humanely euthanized. Tumors are excised, weighed, and photographed. Tumor growth inhibition (TGI) is calculated as: TGI = (1 - (Tt - T0) / (Ct - C0)) x 100%, where T and C represent treatment and control groups, respectively. Tissues are fixed in formalin for histopathology (H&E, IHC), snap-frozen for molecular analysis (Western blot, qPCR, RNA-seq), or processed for pharmacokinetic studies. Blood samples are collected for hematology, clinical chemistry, and drug concentration analysis.

Figure 2: Schematic workflow illustrating the derivation and construction of the KATO III Xenograft Model at Alfa Cytology.

Case Study-KATO III Xenograft Model Development

In a representative preclinical evaluation, KATO III cells were inoculated subcutaneously into immunodeficient mice to establish a gastric cancer xenograft model for assessing the efficacy of a novel therapeutic candidate. Following successful engraftment and tumor growth monitoring, mice were randomized into treatment and control cohorts upon reaching the predetermined tumor volume threshold. The study demonstrated significant tumor growth inhibition in the treatment group compared to vehicle controls, with measurable reductions in tumor volume and weight at the endpoint. Histopathological analysis confirmed treatment-induced changes in tumor architecture, while molecular profiling revealed modulation of key signaling pathways relevant to the mechanism of action. Pharmacokinetic data supported favorable exposure profiles, and no significant body weight loss was observed, indicating an acceptable safety margin. These findings illustrate the KATO III xenograft model's capacity to generate robust, translationally relevant efficacy and safety data to support downstream clinical development decisions. Specific quantitative results and detailed experimental parameters are available upon request and can be customized to align with your compound's development stage and target profile.

Why Choose Alfa Cytology?

Alfa Cytology distinguishes itself as a premier preclinical CRO partner for gastric cancer xenograft research through a combination of technical expertise, operational rigor, and client-centric service delivery. Our KATO III xenograft model service is built on validated protocols, authenticated cell lines, and comprehensive endpoint capabilities designed to maximize the translational value of your preclinical data.

• Authenticated cell line stocks with verified STR profiles and routine mycoplasma screening to ensure genetic fidelity and experimental reproducibility.
• Flexible implantation strategies including subcutaneous, intraperitoneal, orthotopic, and hepatic metastasis models to match your specific research questions.
• Integrated pharmacodynamic and pharmacokinetic analysis with tumor growth inhibition, body weight monitoring, histopathology, and biomarker endpoint evaluation.
• Experienced scientific team with deep expertise in FGFR2-targeted therapy studies, chemoresistance model development, and combination regimen evaluation.
• Customizable study designs with adjustable group sizes, dosing schedules, and endpoint parameters to accommodate diverse therapeutic modalities and development stages.
• Regulatory-compliant documentation and quality assurance processes aligned with preclinical study reporting standards for IND-enabling packages.
• Rapid project initiation with dedicated project management ensuring transparent communication, milestone tracking, and timely data delivery.

Contact Us

Ready to advance your gastric cancer therapeutic program with a validated KATO III xenograft model? Please reach out to us today via our inquiry form or email to learn more about our KATO III Xenograft Model services.

For research use only. Not intended for any clinical use.